Welcome to our dedicated page for Nukkleus SEC filings (Ticker: NUKK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nukkleus Inc. (NASDAQ: NUKK) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents are central to understanding how Nukkleus structures and finances its acquisitions, manages its capital, and consolidates its growing portfolio of defense, aerospace, and advanced manufacturing businesses.
Through current reports on Form 8‑K, Nukkleus details material events such as the completion of its acquisition of Tiltan Software Engineering Ltd., including the purchase price structure, secured promissory note, escrowed common stock, and pledge of the acquired shares. Other 8‑K filings describe shareholder approvals for the acquisition of Star 26 Capital Inc., the issuance of common stock and warrants, and the establishment of a $250 million equity line. Additional 8‑Ks cover the pricing and closing of SC II Acquisition Corp.’s SPAC IPO, where an indirect Nukkleus subsidiary acts as sponsor and Nukkleus’ CEO serves as SC II’s chief executive officer.
Nukkleus’ registration statements on Form S‑1 provide further detail on its capital structure. One S‑1 explains the resale registration of shares issuable upon conversion of Series A Convertible Preferred Stock and the exercise of common stock purchase warrants issued in a private placement. Another S‑1 describes the committed equity financing arrangement with Esousa Group Holdings, LLC, including the mechanics of selling common stock over time under the Common Stock Purchase Agreement and the associated commitment shares.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key terms, such as conversion prices, warrant exercise mechanics, voting results from special and annual meetings, and conditions related to Nasdaq Listing Rules. Users can quickly see how Nukkleus reports acquisitions like Tiltan and Star 26, how it discloses direct financial obligations and pledge agreements, and how equity-linked instruments may affect future common stock issuance. The filings page also provides a structured view of proxy statements, including the DEF 14A describing the Star 26 transaction and related share issuance proposals.
For investors tracking insider and ownership-related information, the NUKK filings set out voting outcomes, equity incentive plan approvals, and the roles of key shareholders and affiliates in transactions such as the Star 26 acquisition and the SC II sponsorship. By combining real-time EDGAR updates with AI explanations, the NUKK SEC filings page helps readers interpret complex legal and financial disclosures in the context of Nukkleus’ broader aerospace and defense acquisition strategy.
Nukkleus Inc. (NUKK) reported that a company director acquired additional common stock through an equity award. On 11/13/2025, the reporting person received 10,000 shares of Nukkleus common stock at a price of $0 per share under the company’s 2025 Equity Incentive Plan in consideration of services rendered to the company. After this transaction, the director beneficially owns 20,000 shares of Nukkleus common stock held directly.
Nukkleus Inc. (NUKK) reported an insider equity grant on a Form 4. A director received 5,000 shares of common stock on 11/13/2025 under the company’s 2025 Equity Incentive Plan as consideration for services to the company. The transaction was recorded at a price of $0.00 per share, reflecting a stock award rather than an open-market purchase. Following this grant, the director now beneficially owns 15,000 shares of Nukkleus common stock in direct ownership.
Nukkleus Inc. (NUKK) reported a director equity award on a Form 4. On 11/13/2025, the reporting person, serving as a director, acquired 5,000 shares of common stock at a price of $0. The filing explains that these shares were issued under the company's 2025 Equity Incentive Plan in consideration for services provided to the company. Following this transaction, the reporting person beneficially owned 15,000 shares of Nukkleus common stock, held directly.
Nukkleus Inc. (NUKK) reported an insider equity award to its Chief Executive Officer and director, Menachem Shalom. On 11/13/2025, he acquired 750,000 shares of Nukkleus common stock at a stated price of $0.00 per share. After this grant, he beneficially owns 1,250,000 shares of common stock in direct ownership. The filing explains that these shares were issued under the company’s 2025 Equity Incentive Plan as consideration for services rendered to Nukkleus.
Nukkleus Inc. reported net income of
Cash was
Nukkleus Inc. (NUKK) reported voting results from its annual meeting held on November 6, 2025. Stockholders elected five directors and ratified the appointment of Somekh Chaikin, a member firm of KPMG International, as independent external auditors for the year ending December 31, 2025.
Shareholders also approved the 2025 Equity Incentive Plan, authorizing 3,950,000 shares of common stock for issuance under the plan. A total of 13,550,766 shares were entitled to vote, and 5,135,897 shares were present or represented by proxy, establishing a quorum.
Nukkleus Inc. (NUKK) called a virtual Special Meeting to seek stockholder approval for four proposals: (1) the Amended and Restated agreement to acquire 100% of Star 26 Capital Inc.; (2) issuance of shares upon exercise of certain outstanding warrants; (3) share issuances under an equity line of credit (ELOC) beyond Nasdaq’s 20% cap; and (4) issuances upon conversion of Series A Preferred Stock beyond the 20% cap.
Under the Star Agreement, consideration includes $21,000,000 (a 12‑month $16,000,000 promissory note and $5,000,000 cash), 4,770,340 NUKK common shares, a five‑year warrant for 12,017,648 shares at $1.50, an additional $3,000,000 cash, and a six‑month $3,000,000 note at 8%.
The Warrant Shares Proposal covers warrants exercisable for 3,191,400 shares at $5.405 for five years. The ELOC permits sales up to the lesser of $250,000,000 or the Nasdaq 20% exchange cap, with approval sought to exceed that cap. The Preferred Stock Conversion Proposal relates to Series A initially convertible into 2,044,800 shares at a $4.89 initial conversion price, subject to a 9.99% beneficial ownership blocker and potential 105% redemption after September 4, 2026 if approval is not obtained. Common shares outstanding were 13,550,766 as of the Record Date.
Nukkleus Inc. (NUKK) insider update: Director and 10% owner Anastasiia Kotaieva reported a gift of 377,432 shares of common stock on 10/24/2025. The transaction price was $0 and is recorded as an indirect holding change via X Group Fund of Funds Limited Partnership. Following the gift, she beneficially owns 1,469,941 shares indirectly. The filing notes the transfer was a gift and states that Ms. Kotaieva is the owner of X Group Family of Funds Limited Partnership.
Nukkleus Inc. (NUKK) furnished a Regulation FD update announcing a press release about the proposed initial public offering of units of SC II Acquisition Corp. I, a newly formed special purpose acquisition company and indirect subsidiary of Nukkleus.
The notice states that a preliminary, subject-to-completion prospectus has been filed with the SEC and is not yet effective, and that no offers or sales of these securities may occur prior to effectiveness. The information under Item 7.01, including the press release attached as Exhibit 99.1, is furnished and not deemed filed under the Exchange Act.
Nukkleus Inc. (NUKK) set its 2025 Annual Meeting for November 6, 2025 at 10:00 a.m. ET, to be held virtually via webcast. Stockholders will vote on three items: electing five directors, ratifying Somekh Chaikin (KPMG member) as independent auditor for the year ending December 31, 2025, and approving the 2025 Equity Incentive Plan.
The plan would reserve 3,950,000 shares for stock-based awards to employees, directors, and consultants, with administration by the Board/Compensation Committee and standard provisions covering options, RSUs, SARs, change-in-control, and termination. The Board recommends voting “FOR” all proposals.
The proxy also details a related-party Star 26 Capital Inc. transaction agreement under which Nukkleus would acquire 100% of Star for consideration including $21,000,000 (a $16,000,000 12‑month note and $5,000,000 cash, less advances), 4,770,340 shares, a 5‑year warrant for 12,017,648 shares at $1.50, an additional $3,000,000 cash and a $3,000,000 6‑month note at 8%, subject to customary closing conditions including stockholder approval under Nasdaq rules. Shares outstanding were 13,550,766 as of October 9, 2025.
FAQ
What is the current stock price of Nukkleus (NUKK)?
What is the market cap of Nukkleus (NUKK)?
